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Purpose: The continual search for new products for soft-tissue augmentation has in recent 
years led to the introduction of long lasting alternatives to hyaluronic acids and collagen that 
are composed of other polymers able to improve clinical persistence over time. This is the first 
report in which sodium carboxymethyl cellulose (CMC) has been chemically treated by the 
cross-linking process and thus used as a hydrogel for soft-tissue augmentation through injection 
with thin needles. The study evaluates, from a clinical point of view, the behavior of cross-linked 
carboxymethyl cellulose hydrogel used in the aesthetic field and its side effects so as to check 
the safety and performance of the polymer following intradermal injections.
Patients and methods: This work shows the preliminary results of an ongoing clinical study 
conducted between 2006 and 2009, performed on 84 healthy volunteers (62 females, 22 males) 
aged between 18 and 72 years, for the treatment of 168 nasolabial folds, 45 perioral wrinkles, 
and 39 lip volume.
Results: Study results show an excellent correction of facial defects. Tolerance and aesthetic 
quality of the correction obtained indicate considerable safety features and absence of side 
effects. From a clinical point of view, hydrogel is gradually absorbed into the injection site 
without migration issues.
Conclusion: Cross-linked CMC hydrogel proves to be an ideal agent for soft tissue augmentation 
with regard to safety and ease of application. It did not cause infection, extrusion, migration, 
or adverse reactions in the patients who have been followed for two years. Delayed aesthetic 
results on facial wrinkles were very satisfactory.
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Introduction
The first injectable heterologous implants date back to 1889 with the introduction of 
paraffin in humans. Because of the important side effects produced, such as pulmonary 
embolism, granulomas, and “paraffinoma”, paraffin was abandoned.1 The use of liquid 
silicone was evaluated from 1961 in the medical field and was successively extended 
to the area of aesthetics.1,2 At the beginning of 20th century, fat autologous implants 
and lipofilling started to be used.3,4 Since 1970, new technologies have allowed the 
reduction of the immunogenic potential of bovine collagen, used for the correction 
of wrinkles and scars.1,5,6 In 1985, different types of collagen were introduced to the 
market,7 followed by other substances, such as hyaluronic acid,8,9 known generically 
as dermal fillers.10–12
Hyaluronic acid and collagen fillers are short-acting. Clinical results disappear 
quickly and may require subsequent applications in order to maintain the aesthetic Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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results.13 Therefore, long lasting alternative substances such 
as calcium hydroxylapatite14,15 and poly-L-lactic acid14,16 have 
appeared with increasing results in recent years.17 However, 
these products have significant limitations. They often cause 
reactive fibrosis of tissues and are only indicated for filling 
into deep tissues. If injected in mid or superficial dermis they 
frequently produce ulcers and granulomas.18,19 Generally they 
prove less manageable than hyaluronic acids and collagen, 
which instead allow a wider range of use.
Carboxymethyl cellulose (CMC) is a biosynthetic sub-
stance neither animal nor human,20 already present in its 
native state in some dermal fillers with carrier15,16 or filling 
function associated with other polymers.21
This is the first report in which CMC has been   chemically 
treated by the cross-linking process and thus used as a 
hydrogel for soft tissue augmentation through injection with 
thin needles.
This study evaluates, from a clinical point of view, the 
behavior of cross-linked carboxymethyl cellulose hydro-
gel used in the aesthetic field and its side effects so as to 
check the safety of the polymer following intradermal 
injections.
Material and methods
Preparation of cross-linked 
carboxymethyl cellulose hydrogel
The preparation of the polymer was carried out by using 
pharmacological grade sodium carboxymethyl cellulose, 
chemically treated with 1,4-Butanediol diglycidyl ether 
cross-linking and subjected to multiple stages of diafiltra-
tion. The purified polymer was therefore suspended in saline 
solution, put in 1 mL syringes and sterilized air-steam cycle 
at 121 degrees. The preparation of tests was performed 
in Italdevice Srl Laboratories (Pomezia, Italy), which are 
certified for the preparation of pharmaceutical and medical 
devices.
The tested product does not contain preservatives such 
as parabens and color additives or any substance prohibited 
by the FDA22 and EEC23 regulations. Substances contained 
in the formula are present in the amounts approved by the 
International Pharmacopoeia.
Specifications of cross-linked 
carboxymethyl cellulose hydrogel
Hydrogel, prepared according to this procedure and used for 
this experiment, showed pH of 7.4 and osmolarity of 318. 
CMC concentration was 20 mg/g and hydrogel particles 
were about 500 microns (485–519 microns) and allowed easy 
injection with 27½ G and 30½ G needles.
Rheometric tests for rheology realized at 25°, 1%, 1 Hz, 
were: a) oscillatory (25°; 1 Hz) vs deformation ampli-
tude 0.1%–1000%; b) oscillatory (25°; 1%) vs frequency 
0.1–40 Hz; c) flow (25°; 3 min) vs velocity 0.1–4 S-1, and 
showed: phase angle (δ) of 28°, storage (elastic) modulus 
(G’) of 70 Pa, viscous (loss) modulus (G’’) of 35 Pa, vis-
cosity (η) of 380 Pa-s. These tests determine: a) maximum 
load applied to the gel without loss of mechanical property, 
which was 30%; b) viscoelasticity, investigating the liquid–
solid behavior of the hydrogel at various conditions, which 
showed a predominantly solid behavior at all frequencies 
investigated; c) phase angle, showed no change in the elastic 
and viscous properties, modifying the frequencies. These 
studies showed a material whose structure is very strong 
even at high deformation, with an identical variation of its 
elastic and viscous properties at different stress conditions 
applied (Figures 1 and 2).
Tests were repeated using cellulase enzyme to break 
the cross-linked network of the gel, after putting into gas 
chromatography on column injection, to assess the fraction 
of the cross-linking residual agent remaining in the hydrogel 
that was lower than one part per million.
All of tests were performed in Laboratories Italdevice 
Srl (Pomezia, Italy).
Clinical tests
This study was performed on 84 healthy volunteers 
(62 females, 22 males) aged between 18 and 72 years, 
(average 44.3), subjected to informed consent about the 
procedure, which was undertaken by four independent 
medical specialists in office-based surgery centers of São 
Paulo and Porto Alegre (Brazil). The study, conducted 
in accordance with the Declaration of Helsinki, was 
approved by respective ethic and research committees in 
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the participating research centers and lasted from June 
2006 to March 2009.
People excluded from the tests were: pregnant women, 
patients younger than 18 years, patients with a tendency to 
develop hypertrophic and keloid scars, patients with burned 
skin or undergoing radiotherapy, patients taking aspirin and 
anticoagulants, patients with inflammation or infection of 
the area to be treated.
Protocol execution of tests
Two weeks before treatment, an intradermal skin test was 
performed by injecting 0.05 mL of cross-linked CMC 
hydrogel in the forearm of each patient in order to check 
local tolerance to the product. Only volunteers in good 
health with healthy and intact skin were chosen for the 
experiment. The application was preceded by asepsis with 
70% alcohol solution.
According to the degree of wrinkle or defect to be cor-
rected, the protocol included one or two treatment sessions, 
seven days apart, in which the maximum amount of the 
product used for each site of infiltration should not have 
exceeded 1 mL.
All tests were performed by injecting CMC into mid 
and deep dermis according to the end use of this device, as 
suggested by researchers. The effectiveness of treatment was 
evaluated on the basis of the double assessment of doctors and 
patients. The evaluation scale was organized as follows:
•	 Index of patients satisfaction in analogical scale: 
  dissatisfied . without visible changes . satisfied . very 
satisfied
•	 Degree of efficacy in doctors opinion:
A: aggravation after treatment; B: without visible changes; 
C: sufficient results; D: good results; E: excellent results.
The evaluation of results had been made on one or more 
defects per patient, before and after each treatment session. 
A subsequent assessment was performed four weeks after 
the last injection. The final evaluation was achieved after 
6 months and after 9 months.
evaluation of adverse reactions
Side effects were analyzed 15 minutes, 1 hour, and 24 hours 
after treatment in all patients, especially those showing 
redness of the treated area. Patients were examined by a 
retrospective analysis for signs of erythema and edema and 
assessed by scores 15 minutes, 1 hour, and 24 hours after 
injection. Reactions are recorded in Table 1. The scores of the 
adverse reactions were obtained by calculating the average 
value of erythema and edema. Results were compared with 
reactivity indices presented in Table 2.
Results
Eighty-four patients had been treated and followed for the 
injection of 168 nasolabial folds, 45 perioral wrinkles, and 
39 lip volume, from June 2006 to March 2009. All patients 
were followed until March 2008 to verify the maintenance of 
the aesthetic result, but only 64 were further monitored over 
time until March 2009 (2 years follow-up) so as to check the 
occurrence of some unexpected event after the total absorp-
tion of the CMC. Twenty patients were re-injected after 
one year from the first treatment (from October 2007 and 
March 2009). For this group of patients long-term studies 
are still ongoing.
Patients through the analogical scale of results positively 
assessed acceptability of treatment. The satisfaction index 
exceeded 90% (see Table 3). After treatment, doctors found 
excellent results in 80% of cases (see Table 4). Patients 
considered the results very satisfactory in 85% of cases for 
nasolabial folds, perioral wrinkles, and lip volume. All treated 
cases showed the decrease of defect depth from the first 
infiltration, sometimes the complete resolution of wrinkles. 
Doctors and patients expressed similar opinions on the quality 
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Figure 2 Flow test – continuous ramp step: rotational viscosity versus shear rate.
Table 1 Intradermal reactivity scores from a clinical point of view
Erythema  Scores Edema Scores
no erythema  0 no edema 0
slight erythema  1 Very slight edema 1
Clearly visible  
erythema 
2 slight edema 2
Moderate erythema  3 Moderate edema about  
1 mm raised skin
3
Marked erythema  4 strong extended edema 4Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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of correction and stability over time, regardless of the type of 
treated wrinkles (Figures 3, 4 and 5). The results remained 
constant for 6 months in most patients. One patient in ten 
showed a more rapid decrease of the correction without 
returning to the initial condition. During this period the 
index of patient satisfaction, after six months, was between 
“satisfied” and “very satisfied, regardless of the type of cor-
rected wrinkles.
Nine months after the first treatment the results were 
still good. The variations obtained with respect to the initial 
condition were judged positively in most cases. After one 
year results remain satisfactory for one third of patients.
Observed adverse effects
About one patient in ten underwent anesthesia. A nonspecific 
slight erythema was noted in less than 1/5 of treated patients 
(14 patients) on injection with spontaneous regression after 
1–36 hours. No granulomas appeared early or late (0%). 
There was no infection (0%), extrusion (0%), or migration 
(0%) confirming the possibility of immediate and safe treat-
ment without preliminary tests.
Local and systemic tolerance
The results of the observed data are presented in Table 5.
Discussion
Carboxymethyl cellulose (CMC) is a biosynthetic sub-
stance based on the b-(1–4)-D-glucopyranose polymer of 
the cellulose, neither animal nor human.20 The available 
literature shows that CMC is an inert substance extremely 
safe and free of mutagenic or carcinogenic outcomes.24 
Some studies underline a bactericidal effect within the 
tissues, thus   making the substance absolutely safe.25 
Presently, the growing success of hyaluronic acid for 
tissue filling is probably due to the possibility of direct 
injection without preliminary skin tests.26 Compared to 
old collagen it proves handy and easy to apply.20 However, 
hyaluronic acid have solution-like behavior at rheology 
low frequency21 and its properties help tissue repair. It also 
has anti-inflammatory functions but no filling function. 
Chemically treated by the cross-linking process, hyaluronic 
acid turns more pseudoplastic and suitable for dermal 
filling,8 although it does not conceptually present specific 
characteristics to that.
The choice of CMC for this study is based on the fact that 
this polymer has got, in its native state, specific characteristics 
for visco-supplementation, densification, and drug delivery.20 
These properties have been received over the last 50 years 
by pharmaceutical companies that still use CMC as a high 
purity excipient for cortisone injections (dexamethasone) 
or an agent of delay (drug delivery) for the release of active 
principles (nifedipina).
Furthermore, CMC can produce tissue filling already in 
its native state. Some fillers (Radiesse®, BioForm Medical, 
Inc, USA; Sculptra®, Sanofi-Aventis Spa, IT; Laresse™, 
FzioMed, Inc, USA) use CMC with carrier or filling 
function.15,16,21
Despite having higher filling qualities than native 
hyaluronic acids, the native CMC (ie, non cross-linked), 
has got lower performance characteristics than cross-
linked hyaluronic acids. Therefore the companies that until 
now have tried to use the native CMC for tissue filling 
Figure 3 Before (left) and one month after (right) treatment of nasolabial folds with 
1 mL of cross-linked CMC for each side.
Table 4 Degree of efficacy in doctors opinion
Follow  
up
Degree of efficacy in doctors opinion
Aggravation  
after 
treatment
Without  
visible 
changes
Sufficient 
results
Good 
results
Excellent 
results
4 weeks 0 1 4 12 67
6 months 0 1 8 26 49
9 months 0 1 56 27 0
Table 3 Index of patients satisfaction
Follow up Index of patients satisfaction
Dissatisfied Without  
visible  
changes
Satisfied Very  
satisfied
4 weeks  0 2 11 71
6 months 0 2 50 32
9 months 0 2 58 24
Table 2 Reactivity indices (Draize classification)
Index Classification
,0.5 non reactive
0.5–2.0 slightly reactive
2.0–5.0 Moderately reactive
5.0–8.0 highly reactiveClinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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The re-injection performed on the same site of the 
first infiltration does not produce side effects in the   short- and 
long-term. The re-injection aiming at additional correction of 
wrinkles requires a few days off after the first application.
The persistence of the hydrogel has been demonstrated 
within the tissue injected in dermal areas. From a clini-
cal point of view, hydrogel is gradually absorbed into the 
injection site without migration issues. The polymer can 
be injected with very thin needles (30½ G) confirming the 
absolute flexibility and manageability of cross-linked CMC 
hydrogel.
Conclusion
In conclusion, cross-linked CMC hydrogel proves to be 
an ideal agent for facial wrinkles with regard to safety and 
ease of application. It did not cause infection, extrusion, 
migration, or adverse effects in the patients who have been 
followed for two years (some of them were monitored for a 
further 12 months after the total re-absorption of the poly-
mer). A slight erythema visible as redness was noted only 
in few patients and disappeared within an acceptable term 
(1–36 hours). Delayed aesthetic results on facial wrinkles 
were very satisfactory.
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